AAV Vector Design Service for Single Gene Delivery
Introduction
Creative Biolabs' Single Gene Delivery service addresses single-gene disorder therapy development challenges by providing high-quality, customized AAV vectors. These enable precise, efficient therapeutic gene delivery, bypassing traditional drug development barriers to offer potential one-time cures. Our comprehensive solution includes tailored vectors (gene of interest, regulatory elements, targeted capsid) for optimal expression, supporting research, preclinical studies, and clinical production.
Discover How We Can Help - Request a Consultation
Single-gene delivery is a core gene therapy approach, introducing functional genes to correct defects or add therapeutic functions. It excels for monogenic disorders like hemophilia, cystic fibrosis, and spinal muscular atrophy. Advances in viral vectors, especially AAV, have made it a promising, clinically viable strategy—AAV's non-pathogenicity and capacity for long-term expression in non-dividing cells are key to this.
Single Gene Delivery
The precision of single-gene delivery hinges on sophisticated vector design and engineering. We customize AAV vectors to optimize gene expression and cellular tropism. The core of our design process is the expression cassette, a carefully constructed sequence that contains the gene of interest, a promoter to drive expression, and other regulatory elements. This cassette is then packaged into the AAV capsid.
| Gene Target | Associated Disease | Target Tissues and Cells | Commonly Used AAV Serotypes |
|---|---|---|---|
| F8 | Hemophilia A | Liver hepatocytes | AAV8, AAV5 |
| F9 | Hemophilia B | Liver hepatocytes | AAV8, AAV9 |
| CFTR | Cystic Fibrosis | Respiratory epithelial cells, pancreatic cells | AAV2, AAV5 |
| SMN1 | Spinal Muscular Atrophy (SMA) | Spinal cord motor neurons, muscle cells | AAV9, AAVrh10 |
| DMD | Duchenne Muscular Dystrophy | Skeletal muscle cells, cardiac muscle cells | AAV1, AAV6, AAV9 |
| HTT | Huntington's Disease | Brain striatal neurons | AAV2, AAV5 |
| BDNF | Alzheimer's Disease, Parkinson's Disease | Brain hippocampal neurons, substantia nigra dopaminergic neurons | AAV2, AAV9 |
| LDLR | Familial Hypercholesterolemia | Liver hepatocytes | AAV8, AAV5 |
| GBA | Gaucher Disease | Liver cells, macrophages | AAV2, AAVrh10 |
| ABCA4 | Retinitis Pigmentosa | Retinal photoreceptor cells, retinal pigment epithelial cells | AAV2, AAV5 |
Advantages
- Exceptional Safety Profile: They are non-pathogenic and do not integrate into the host genome, significantly reducing the risk of insertional mutagenesis.
- Long-Term Expression: The delivered gene can persist for years as a stable episome, offering the potential for a one-time treatment.
- Low Immunogenicity: The virus's low immunogenicity allows for effective gene expression without a strong, therapy-limiting reaction from the patient's immune system.
- Broad Tissue Tropism: AAV serotypes can be selected to target a wide variety of tissues, making it a versatile tool for treating diverse diseases.
Workflow
- Required Starting Materials: Project initiation requires your target gene sequence (cDNA/genomic DNA), desired regulatory elements (e.g., promoters), and a clear target cell/tissue definition for custom AAV design.
- Vector Design & Serotype Selection: Analyze target cells to select optimal AAV serotype; design expression cassette with suitable promoter/regulatory elements for robust, stable expression.
- Plasmid Construction: Assemble three key plasmids (transfer, packaging, helper) to ensure safe, non-replicative final vectors.
- Virus Packaging & Purification: Use triple-plasmid transfection to package genes into AAV; purify via advanced chromatography for high purity and potency.
- Quality Control & Characterization: Rigorous QC tests (gene expression, titer, purity, sterility, endotoxin) to guarantee product quality.
- Final Delivery: Provide final AAV vector with comprehensive report (QC data, vector characterization).
-
Final Deliverables:
- A ready-to-use, high-titer AAV vector.
- A Certificate of Analysis detailing vector titer, purity, and sterility.
- A comprehensive project report with a complete summary of the vector design, production process, and quality control results.
- Estimated Timeframe: The typical timeframe for our service ranges from 8 to 12 weeks, depending on the complexity of the gene and the specific serotype required for your project.
What We Can Offer
As a leading partner in gene therapy research, Creative Biolabs' Single Gene Delivery service provides unparalleled expertise and resources for your project.
Customized, end-to-end service
One-stop solution for Single Gene Delivery—from vector design to large-scale clinical-grade production.
Scalable and optimized processes
Efficient upstream/downstream development with large-scale fermentation, supporting varied project scales while maintaining top quality.
Robust quality assurance
Operates under an established quality system (QbD, PAT); strict aseptic verification and GMP-certified processes ensure product quality.
Precision and stability
Guarantees strain stability in cell banks/fermentations; optimizes gene codon usage for high-level expression.
Flexible and high-standard production
Fermentation in batch/fed-batch/continuous mode (optimized conditions for yield/efficacy); adheres to HACCP/GMP, with rigorous QC tools.
Experience the Creative Biolabs Advantage - Get a Quote Today
Customer Reviews
FAQs
What is the primary advantage of AAV over other viral vectors like lentivirus?
AAV vectors offer a significant safety advantage. Unlike lentiviruses, AAV is a non-integrating vector, meaning the delivered gene remains as a stable episome and does not insert into the host genome. This drastically reduces the risk of insertional mutagenesis, a potential side effect associated with integrating vectors.
How do you ensure the gene is delivered to the right cells and tissues?
We achieve tissue specificity by carefully selecting the most appropriate AAV serotype based on your target cell type. Different serotypes naturally have a preference for certain tissues. For more challenging targets, we can use advanced capsid engineering techniques to further enhance specificity and precision.
What kind of quality control is performed on your AAV vectors?
We adhere to the highest quality standards. Every batch of our AAV vectors undergoes a rigorous quality control process that includes titer determination, sterility testing, purity analysis, and endotoxin level measurement to ensure a safe, high-quality, and reproducible product for your research.
I am new to gene therapy. Can you help me design the expression cassette for my project?
Absolutely. Our team of experts is ready to assist you. We can help you select the optimal promoter and regulatory elements for your gene to ensure efficient and stable expression in your target cells. Please feel free to reach out to our consultation team with the details of your project.
Contact Our Team for More Information and to Discuss Your Project
